Market cap
$7,129 Mln
Market cap
$7,129 Mln
Revenue (TTM)
$1,313 Mln
P/E Ratio
33.9
P/B Ratio
3.4
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
0.1 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
16
Debt to Equity
0.5
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
84,478,406
CFO
$1,104.25 Mln
EBITDA
$1,281.24 Mln
Net Profit
$208.19 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
HealthEquity (HQY)
| -9.9 | 5.3 | -16.2 | 7.5 | 13.1 | 4.1 | 12.5 |
|
BSE Sensex
| -9.5 | -2.9 | -9.0 | 3.2 | 8.6 | 9.0 | 12.0 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
HealthEquity (HQY)
| -4.5 | 44.3 | 7.6 | 39.3 | -36.5 | -5.9 | 24.2 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
HealthEquity (HQY)
|
82.5 | 7,128.8 | 1,313.4 | 215.2 | 24.6 | 10.2 | 33.9 | 3.4 |
| 5.7 | 1,516.6 | 790.8 | -189.0 | -22.5 | -99.1 | -- | 9.8 | |
| 22.4 | 3,440.3 | 1,177.3 | 101.3 | 8.8 | -198.6 | 41.4 | 31.8 | |
| 20.7 | 2,623.5 | 738.2 | -131.3 | -18.9 | -23.9 | -- | 4.3 | |
| 20.1 | 3,872.2 | 956.8 | -56.0 | -7.2 | -6.3 | -- | 3.9 | |
| 17.6 | 2,010.5 | 594.8 | 5.2 | 3.2 | 0.5 | 347.2 | 1.9 | |
| 8.7 | 3,799.0 | 709.0 | -679.4 | -12.9 | 466.8 | -- | 18.7 | |
| 11.9 | 7,323.8 | 1,071.4 | -270.1 | -28.1 | -42.9 | -- | 1.1 | |
| 12.8 | 4,597.1 | 1,001.3 | -450.7 | -32.5 | -29 | -- | 3.2 | |
| 10.0 | 5,962.5 | 1,610.6 | 282.3 | 3.6 | 14.4 | 21.4 | 2.8 |
HealthEquity, Inc. provides technology-enabled services platforms to consumers and employers in the United States. It offers health savings accounts (HAS); investment platform; online-only automated investment advisory services through Advisor, a... Web-based tool. The company also provides flexible spending accounts (FSA) for health and dependent care; health reimbursement arrangements; and Consolidated Omnibus Budget Reconciliation Act continuation services, as well as administers pre-tax commuter benefit programs. In addition, the company offers HSA and FSA members with access to certain healthcare products, programs, and services through its marketplace. It serves clients through a direct sales force; and brokers and advisors, a network of health plans, benefits administrators, benefits brokers and consultants, and retirement plan record-keepers. HealthEquity, Inc. was incorporated in 2002 and is based in Draper, Utah. Address: 15 West Scenic Pointe Drive, Draper, UT, United States, 84020 Read more
President, CEO & Director
Mr. Jon Kessler
President, CEO & Director
Mr. Jon Kessler
Headquarters
Draper, UT
Website
The share price of HealthEquity Inc (HQY) is $82.53 (NASDAQ) as of 09-Apr-2026 10:39 EDT. HealthEquity Inc (HQY) has given a return of 13.13% in the last 3 years.
The P/E ratio of HealthEquity Inc (HQY) is 33.92 times as on 07-Apr-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2026
|
--
|
--
|
|
2025
|
--
|
--
|
|
2024
|
--
|
--
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
The 52-week high and low of HealthEquity Inc (HQY) are Rs 116.65 and Rs 72.76 as of 09-Apr-2026.
HealthEquity Inc (HQY) has a market capitalisation of $ 7,129 Mln as on 07-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in HealthEquity Inc (HQY), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.